The recommended safe dosage of erythromycin for a child is 20 mg/kg/day in four equal doses. The child weighs 33 lb. The medication is supplied in 125 mg/mL. What is the safe and therapeutic dosage for this child?

Choice A reason: Diazepam is effective for acute seizures but is less preferred for status epilepticus due to its shorter duration and risk of accumulation with repeated doses. It acts on GABA receptors but is less practical for sustained control in emergencies.
Choice B reason: Midazolam is the drug of choice for status epilepticus due to its rapid onset and short half-life, allowing quick seizure termination via GABA receptor enhancement. Its intramuscular or intranasal administration is practical in emergencies, ensuring prompt control of prolonged seizures.
Choice C reason: Valproic acid is used for long-term seizure management, not acute status epilepticus. Its slower onset and oral/IV administration are less effective for rapid seizure termination, as it modulates sodium channels and GABA but requires time to reach therapeutic levels.
Choice D reason: Carbamazepine is a long-term antiepileptic, not suitable for status epilepticus. It stabilizes sodium channels to prevent seizures but lacks the rapid onset needed for emergency treatment, making it inappropriate for acute, life-threatening seizure activity.

Choice A reason: Warm baths may help with MS-related spasticity but are not the priority teaching for cyclophosphamide and methylprednisolone. These drugs focus on immunosuppression and inflammation control, and baths do not address their side effects or infection risks.
Choice B reason: Cyclophosphamide and methylprednisolone are immunosuppressants, reducing white blood cell counts and increasing infection risk. Avoiding crowds and sick individuals minimizes exposure to pathogens, critical for preventing infections like pneumonia in MS patients on these medications.
Choice C reason: Using a walker supports mobility in MS without necessarily weakening gait. It aids safety during exacerbations, and discouraging its use is inappropriate, as it does not address the immunosuppressive risks of the prescribed medications.
Choice D reason: Taking cyclophosphamide and methylprednisolone only when symptoms occur is incorrect, as these drugs require consistent dosing for immunosuppression and inflammation control. Symptom-based dosing reduces efficacy and increases relapse risk in MS management.